129
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Natural furin inhibitor(s) as potent therapeutic molecule to mitigate SARS-CoV-2 infection

ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 7365-7371 | Received 02 May 2022, Accepted 29 Aug 2022, Published online: 13 Sep 2022

References

  • Azhar, E. I., Hui, D. S. C., Memish, Z. A., Drosten, C., & Zumla, A. (2019). The Middle East Respiratory Syndrome (MERS). Infectious Disease Clinics of North America, 33(4), 891–905. https://doi.org/10.1016/j.idc.2019.08.001
  • Belouzard, S., Chu, V. C., & Whittaker, G. R. (2009). Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proceedings of the National Academy of Sciences of the United States of America, 106(14), 5871–5876. https://doi.org/10.1073/pnas.0809524106
  • Boehm, M., & Nabel, E. G. (2002). Angiotensin-converting enzyme 2—A new cardiac regulator. The New England Journal of Medicine, 347(22), 1795–1797. https://doi.org/10.1056/NEJMcibr022472
  • Couture, F., Kwiatkowska, A., Dory, Y. L., & Day, R. (2015). Therapeutic uses of furin and its inhibitors: A patent review. Expert Opinion on Therapeutic Patents, 25(4), 379–396. https://doi.org/10.1517/13543776.2014.1000303
  • Dales, N. A., Gould, A. E., Brown, J. A., Calderwood, E. F., Guan, B., Minor, C. A., Gavin, J. M., Hales, P., Kaushik, V. K., Stewart, M., Tummino, P. J., Vickers, C. S., Ocain, T. D., & Patane, M. A. (2002). Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. Journal of the American Chemical Society, 124(40), 11852–11853. https://doi.org/10.1021/ja0277226
  • Fang, L., Karakiulakis, G., & Roth, M. (2020). Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet Respiratory Medicine, 8(4), e21. https://doi.org/10.1016/S2213-2600(20)30116-8
  • Ferrario, C. M., Jessup, J., Chappell, M. C., Averill, D. B., Brosnihan, K. B., Tallant, E. A., Diz, D. I., & Gallagher, P. E. (2005). Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation, 111(20), 2605–2610. https://doi.org/10.1161/CIRCULATIONAHA.104.510461
  • Furin cleavage site in the SARS-CoV-2 coronavirus glycoprotein.
  • GISAID Global Initiative on Sharing All Influenza Data. Phylogeny of SARS-like betacoronaviruses including novel coronavirus (nCoV).
  • Huang, M-l., Li, X., Meng, Y., Xiao, B., Ma, Q., Ying, S-s., Wu, P-s., & Zhang, Z-s (2010). Upregulation of angiotensin‐converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors. Clinical and Experimental Pharmacology & Physiology, 37(1), e1–e6. https://doi.org/10.1111/j.1440-1681.2009.05302.x
  • Jaaks, P., & Bernasconi, M. (2017). The proprotein convertase furin in tumour progression. International Journal of Cancer, 141(4), 654–663. https://doi.org/10.1002/ijc.30714
  • Kirchdoerfer, R. N., Cottrell, C. A., Wang, N., Pallesen, J., Yassine, H. M., Turner, H. L., Corbett, K. S., Graham, B. S., McLellan, J. S., & Ward, A. B. (2016). Pre-fusion structure of a human coronavirus spike protein. Nature, 531(7592), 118–121. https://doi.org/10.1038/nature17200
  • Lam, C. W., Chan, M. H., & Wong, C. K. (2004). Severe acute respiratory syndrome: Clinical and laboratory manifestations. The Clinical Biochemist. Reviews, 25(2), 121–132.
  • Mahdevar, E. (2021). Exploring the cancer-testis antigen BORIS to design a novel multi-epitope vaccine against breast cancer based on immunoinformatics approaches. Journal of Biomolecular Structure and Dynamics, 1–18. https://doi.org/10.1080/07391102.2021.1883111
  • Millet, J. K., & Whittaker, G. R. (2014). Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proceedings of the National Academy of Sciences of the United States of America, 111(42), 15214–15219. https://doi.org/10.1073/pnas.1407087111
  • Prompetchara, E., Ketloy, C., & Palaga, T. (2020). Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pacific Journal of Allergy and Immunology, 38(1), 1–9.
  • Roncati, L., Gallo, G., Manenti, A., & Palmieri, B. (2020). Renin-angiotensin system: The unexpected flaw inside the human immune system revealed by SARS-CoV-2. Medical Hypotheses, 140, 109686. https://doi.org/10.1016/j.mehy.2020.109686
  • Rottier, P. J. (1995). The coronaviridae. (pp. 115–139). Springer.
  • Safavi, A., Kefayat, A., Abiri, A., Mahdevar, E., Behnia, A. H., & Ghahremani, F. (2019). In silico analysis of transmembrane protein 31 (TMEM31) antigen to design novel multiepitope peptide and DNA cancer vaccines against melanoma. Molecular Immunology, 112, 93–102. https://doi.org/10.1016/j.molimm.2019.04.030
  • Safavi, A., Kefayat, A., Sotoodehnejadnematalahi, F., Salehi, M., & Modarressi, M. H. (2019). In silico analysis of synaptonemal complex protein 1 (SYCP1) and acrosin binding protein (ACRBP) antigens to design novel multiepitope peptide cancer vaccine against breast cancer. International Journal of Peptide Research and Therapeutics, 25(4), 1343–1359. https://doi.org/10.1007/s10989-018-9780-z
  • Tyrrell, D. A., & Bynoe, M. L. (1966). Cultivation of viruses from a high proportion of patients with colds. Lancet (London, England), 1(7428), 76–77. https://doi.org/10.1016/S0140-6736(66)92364-6
  • van Doremalen, N., Bushmaker, T., Morris, D. H., Holbrook, M. G., Gamble, A., Williamson, B. N., Tamin, A., Harcourt, J. L., Thornburg, N. J., Gerber, S. I., Lloyd-Smith, J. O., de Wit, E., & Munster, V. J. (2020). Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. The New England Journal of Medicine, 382(16), 1564–1567. https://doi.org/10.1056/NEJMc2004973
  • Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020). Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell, 181(2), 281–292.e6. e286 https://doi.org/10.1016/j.cell.2020.02.058
  • Weekly epidemiological update on COVID-19 - 10 (August 2022).
  • WHO Situation Report (2020).
  • Why the Coronavirus Has Been So Successful. (2020). By Ed Yong March 20, 2020.
  • World Health Organization. WHO Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020.
  • Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., Yuan, M.-L., Zhang, Y.-L., Dai, F.-H., Liu, Y., Wang, Q.-M., Zheng, J.-J., Xu, L., Holmes, E. C., & Zhang, Y.-Z. (2020). A new coronavirus associated with human respiratory disease in China. Nature, 579(7798), 265–269. https://doi.org/10.1038/s41586-020-2008-3
  • Wu, Y., & Zhao, S. (2020). Furin cleavage sites naturally occur in coronaviruses. Stem Cell Research, 50, 102115. https://doi.org/10.1016/j.scr.2020.102115
  • Xia, S., Zhu, Y., Liu, M., Lan, Q., Xu, W., Wu, Y., Ying, T., Liu, S., Shi, Z., Jiang, S., & Lu, L. (2020). Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cellular & Molecular Immunology, 17(7), 765–767. https://doi.org/10.1038/s41423-020-0374-2
  • Zhang, H., Penninger, J. M., Li, Y., Zhong, N., & Slutsky, A. S. (2020). Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target. Intensive Care Medicine, 46(4), 586–590. https://doi.org/10.1007/s00134-020-05985-9
  • Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., Chen, H.-D., Chen, J., Luo, Y., Guo, H., Jiang, R.-D., Liu, M.-Q., Chen, Y., Shen, X.-R., Wang, X., … Shi, Z.-L. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579(7798), 270–273. https://doi.org/10.1038/s41586-020-2012-7
  • Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., Niu, P., Zhan, F., Ma, X., Wang, D., Xu, W., Wu, G., Gao, G. F., & Tan, W, China Novel Coronavirus Investigating and Research Team (2020). A novel coronavirus from patients with pneumonia in China, 2019. The New England Journal of Medicine, 382(8), 727–733. https://doi.org/10.1056/NEJMoa2001017

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.